LAE-32

D-Lysergic acid ethylamide (LAE-32) is psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).^[1][2] It is reported to have some LSD-like effects but is weaker and shorter lasting, with an active dose reported to be between 0.5 and 1.4 mg.^[1][3]

LAE-32

Clinical data
Other names	LAE32; LAE; LSE; Lysergic acid ethylamide; Lysergic acid monoethylamide; N-Ethyllysergamide; NE-LA; N-Ethylergine; N-Ethyl-LSA; N-Ethyl-6-methyl-9,10-didehydroergoline-8β-carboxamide
Routes of administration	Oral
Drug class	Serotonergic psychedelic; Hallucinogen
Identifiers
IUPAC name (8β)-N-Ethyl-6-methyl-9,10-didehydroergoline-8-carboxamide
CAS Number	478-99-9 Y
PubChem CID	101704
ChemSpider	19975296 Y
UNII	72370WPF0J
CompTox Dashboard (EPA)	DTXSID20963946
Chemical and physical data
Formula	C18H21N3O
Molar mass	295.386 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCNC(=O)[C@@H]2C=C1c3cccc4[nH]cc(C[C@H]1N(C)C2)c34
InChI InChI=1S/C18H21N3O/c1-3-19-18(22)12-7-14-13-5-4-6-15-17(13)11(9-20-15)8-16(14)21(2)10-12/h4-7,9,12,16,20H,3,8,10H2,1-2H3,(H,19,22)/t12-,16-/m1/s1 Y Key:VEBWTGYUIBTVNR-MLGOLLRUSA-N Y
(verify)

It was studied by the CIA as part of Project MKULTRA. Documents published by the CIA under the Freedom of Information Act suggest it causes "a schizophrenia-like condition" but it allows people with schizophrenia to remain indifferent to their disorder.^{[citation needed]} The drug has also been studied in psychedelic-assisted psychotherapy.^[3]

LAE-32 was first described in the scientific literature by Albert Hofmann and colleagues by 1955.^[4]

See also

• Substituted lysergamide
• Lysergic acid methylamide
• Lysergic acid propylamide